JP6175078B2 - 新規のシステインプロテアーゼ阻害剤及びその使用 - Google Patents
新規のシステインプロテアーゼ阻害剤及びその使用 Download PDFInfo
- Publication number
- JP6175078B2 JP6175078B2 JP2014555762A JP2014555762A JP6175078B2 JP 6175078 B2 JP6175078 B2 JP 6175078B2 JP 2014555762 A JP2014555762 A JP 2014555762A JP 2014555762 A JP2014555762 A JP 2014555762A JP 6175078 B2 JP6175078 B2 JP 6175078B2
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- alkyl
- nmr
- mhz
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/48—Compounds containing oxirane rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Enzymes And Modification Thereof (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261593664P | 2012-02-01 | 2012-02-01 | |
| US61/593,664 | 2012-02-01 | ||
| PCT/US2013/024364 WO2013116663A1 (en) | 2012-02-01 | 2013-02-01 | Novel cysteine protease inhibitors and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015510508A JP2015510508A (ja) | 2015-04-09 |
| JP2015510508A5 JP2015510508A5 (enExample) | 2016-03-24 |
| JP6175078B2 true JP6175078B2 (ja) | 2017-08-02 |
Family
ID=48905878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014555762A Expired - Fee Related JP6175078B2 (ja) | 2012-02-01 | 2013-02-01 | 新規のシステインプロテアーゼ阻害剤及びその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US9403843B2 (enExample) |
| EP (1) | EP2811999B1 (enExample) |
| JP (1) | JP6175078B2 (enExample) |
| WO (1) | WO2013116663A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2811999B1 (en) * | 2012-02-01 | 2021-10-27 | The Trustees of Columbia University in the City of New York | Novel cysteine protease inhibitors and uses thereof |
| JP6768270B2 (ja) * | 2015-08-03 | 2020-10-14 | 学校法人神戸学院 | ビオチン直接結合型タンパク質活性調節物質 |
| US12282014B2 (en) | 2015-11-19 | 2025-04-22 | Dana-Farber Cancer Institute, Inc. | Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers |
| EP3746124A4 (en) | 2018-01-30 | 2021-10-27 | Foghorn Therapeutics Inc. | COMPOUNDS AND THEIR USES |
| US12473334B2 (en) | 2018-10-17 | 2025-11-18 | Dana-Farber Cancer Institute, Inc. | SWI/SNF family chromatin remodeling complexes and uses thereof |
| US12384776B2 (en) | 2019-01-29 | 2025-08-12 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2020160100A1 (en) | 2019-01-29 | 2020-08-06 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| CN115023226A (zh) | 2020-01-29 | 2022-09-06 | 福宏治疗公司 | 化合物及其用途 |
| US12383555B2 (en) | 2020-05-20 | 2025-08-12 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| CN112321686B (zh) * | 2020-11-16 | 2022-07-05 | 北京大学深圳研究生院 | 一种靶向新冠肺炎病毒刺突蛋白的稳定多肽及其用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5942672B2 (ja) * | 1975-08-11 | 1984-10-16 | 大正製薬株式会社 | ロイシルアグマチン化合物の製造法 |
| JPS5547668A (en) * | 1978-09-30 | 1980-04-04 | Taisho Pharmaceut Co Ltd | Epoxysuccinamic acid |
| JPS55115878A (en) * | 1979-02-27 | 1980-09-06 | Taisho Pharmaceut Co Ltd | Epoxysuccinic acid derivative |
| JPH08104683A (ja) * | 1993-10-29 | 1996-04-23 | Takeda Chem Ind Ltd | エポキシコハク酸誘導体 |
| WO1995032954A1 (en) * | 1994-05-31 | 1995-12-07 | Takeda Chemical Industries, Ltd. | Epoxysuccinic acid derivatives, their production and use |
| JPH08119983A (ja) * | 1994-07-08 | 1996-05-14 | Fujisawa Pharmaceut Co Ltd | 新規化合物ｗｆ１４８６５、その製造方法およびその用途 |
| WO1998047887A1 (en) | 1997-04-18 | 1998-10-29 | Taiho Pharmaceutical Co., Ltd. | Novel epoxysuccinamide derivatives or salts thereof |
| AUPS192602A0 (en) * | 2002-04-23 | 2002-05-30 | Resmed Limited | Nasal mask |
| KR20090029725A (ko) | 2006-06-13 | 2009-03-23 | 더 보드 오브 트러스티즈 오프 더 리랜드 스탠포드 쥬니어 유니버시티 | 시스테인 프로테아제의 에폭시드 저해물질 |
| WO2010074783A1 (en) | 2008-12-23 | 2010-07-01 | The Trustees Of Columbia University In The City Of New York | Phosphodiesterase inhibitors and uses thereof |
| US20110105603A1 (en) * | 2010-08-06 | 2011-05-05 | American Life Science Pharmaceuticals, Inc. | Compositions and methods for treating beta-amyloid related diseases |
| ES2764999T3 (es) | 2009-12-10 | 2020-06-05 | Univ Columbia | Activadores de histona acetiltransferasa y usos de los mismos |
| EP3323813B1 (en) | 2010-12-22 | 2020-08-26 | The Trustees of Columbia University in the City of New York | Histone acetyltransferase modulators and uses thereof |
| EP2811999B1 (en) * | 2012-02-01 | 2021-10-27 | The Trustees of Columbia University in the City of New York | Novel cysteine protease inhibitors and uses thereof |
-
2013
- 2013-02-01 EP EP13743556.6A patent/EP2811999B1/en not_active Not-in-force
- 2013-02-01 JP JP2014555762A patent/JP6175078B2/ja not_active Expired - Fee Related
- 2013-02-01 US US14/376,361 patent/US9403843B2/en active Active
- 2013-02-01 WO PCT/US2013/024364 patent/WO2013116663A1/en not_active Ceased
-
2016
- 2016-06-24 US US15/192,113 patent/US10647709B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013116663A1 (en) | 2013-08-08 |
| EP2811999A4 (en) | 2015-09-23 |
| US9403843B2 (en) | 2016-08-02 |
| US10647709B2 (en) | 2020-05-12 |
| US20150045393A1 (en) | 2015-02-12 |
| EP2811999A1 (en) | 2014-12-17 |
| US20170008884A1 (en) | 2017-01-12 |
| JP2015510508A (ja) | 2015-04-09 |
| EP2811999B1 (en) | 2021-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6175078B2 (ja) | 新規のシステインプロテアーゼ阻害剤及びその使用 | |
| JP5670754B2 (ja) | カテプシンｓ阻害剤としてのフロ［３，２−ｂ］ピロール−３−オン | |
| US12209081B2 (en) | Heterocycle derivatives for treating TRPM3 mediated disorders | |
| JP2020524158A (ja) | Ｓｓａｏ阻害剤 | |
| JPWO1998009949A1 (ja) | 新規アセトアミド誘導体およびプロテアーゼ阻害剤 | |
| AU2021394226B2 (en) | Benzylamine or benzyl alcohol derivative and use thereof | |
| WO2016112295A1 (en) | Compounds that participate in cooperative binding and uses thereof | |
| SA111320683B1 (ar) | معززات من n-اسيل سلفوناميد لموت الخلايا المبرمج | |
| JP2011518120A (ja) | 化合物 | |
| BG65132B1 (bg) | N-[5-[[[5-алкил-2-оксазолил]метил]тио]-2-тиазолил]- карбоксамидни производни, фьрмацевтичен състав и използването им като инхибитори на циклин зависими кинази | |
| EP4038064B1 (en) | N-substututed-6-oxo-1,6-dihydropyrimidine-2-yl derivatives as inhibitors of the human immunodeficiency virus replication | |
| KR20010041406A (ko) | 시스테인 활성-의존 효소의 저해제로 유용한 티아디아졸화합물 | |
| US8119673B2 (en) | Compounds 148 | |
| US20230099089A1 (en) | Antiviral substances with a wide spectrum of activity | |
| CA3211625A1 (en) | 1,3,4-oxadiazole thiocarbonyl compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same | |
| Pan et al. | Discovery of (S)-6-methoxy-chroman-3-carboxylic acid (4-pyridin-4-yl-phenyl)-amide as potent and isoform selective ROCK2 inhibitors | |
| KR102537616B1 (ko) | 히스톤 탈아세틸화 효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 | |
| EP3733684A1 (en) | Ursodeoxycholic acid derivatives for the treatment of polycystic diseases | |
| JP2000502997A (ja) | レトロウイルスプロテアーゼ抑制化合物 | |
| EP3328833B1 (en) | Selective inhibitors of carbonic anhydrase | |
| CA2972994A1 (en) | Pyrazole compounds | |
| WO2015063544A1 (en) | Novel substituted 2-aminoquinazolin-4(3h)-one derivatives as malarial aspartic protease inhibitors | |
| WO2023233024A1 (en) | Dpp9 binding compounds | |
| KR20200123021A (ko) | 캐스파제 저해제의 프로드럭 | |
| WO2016205031A1 (en) | Fluoropyridyl pyrazol compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160201 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160201 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160818 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160912 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20161208 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170313 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170426 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170529 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170607 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170707 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6175078 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |